nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—muscle cancer—hematologic cancer	0.326	1	CtDrD
Methotrexate—ABCC3—hematologic cancer	0.0749	0.395	CbGaD
Methotrexate—MTHFR—hematologic cancer	0.0475	0.25	CbGaD
Methotrexate—ABCG2—hematologic cancer	0.0364	0.192	CbGaD
Methotrexate—PGD—Dacarbazine—hematologic cancer	0.0223	0.0814	CbGbCtD
Methotrexate—ABCC10—Daunorubicin—hematologic cancer	0.0164	0.0597	CbGbCtD
Methotrexate—ALB—hematologic cancer	0.0159	0.0836	CbGaD
Methotrexate—ABCB1—hematologic cancer	0.0151	0.0798	CbGaD
Methotrexate—ABCC4—Tioguanine—hematologic cancer	0.0147	0.0535	CbGbCtD
Methotrexate—ABCC10—Cytarabine—hematologic cancer	0.0144	0.0527	CbGbCtD
Methotrexate—AOX1—Mercaptopurine—hematologic cancer	0.012	0.0438	CbGbCtD
Methotrexate—TYMS—Gemcitabine—hematologic cancer	0.0106	0.0389	CbGbCtD
Methotrexate—ABCC1—Idarubicin—hematologic cancer	0.00892	0.0326	CbGbCtD
Methotrexate—ABCC10—Gemcitabine—hematologic cancer	0.00878	0.032	CbGbCtD
Methotrexate—SLCO1A2—Chlorambucil—hematologic cancer	0.00797	0.0291	CbGbCtD
Methotrexate—ABCG2—Clofarabine—hematologic cancer	0.00721	0.0263	CbGbCtD
Methotrexate—ABCC10—Vincristine—hematologic cancer	0.00684	0.025	CbGbCtD
Methotrexate—ABCC1—Daunorubicin—hematologic cancer	0.00631	0.0231	CbGbCtD
Methotrexate—ABCC10—Etoposide—hematologic cancer	0.00627	0.0229	CbGbCtD
Methotrexate—ABCC4—Mercaptopurine—hematologic cancer	0.00608	0.0222	CbGbCtD
Methotrexate—ABCC2—Daunorubicin—hematologic cancer	0.00467	0.0171	CbGbCtD
Methotrexate—ABCC3—Vincristine—hematologic cancer	0.0043	0.0157	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—hematologic cancer	0.00427	0.0156	CbGbCtD
Methotrexate—ABCG2—Daunorubicin—hematologic cancer	0.00423	0.0154	CbGbCtD
Methotrexate—ABCC3—Cisplatin—hematologic cancer	0.00401	0.0146	CbGbCtD
Methotrexate—ABCC3—Etoposide—hematologic cancer	0.00394	0.0144	CbGbCtD
Methotrexate—ABCC1—Mitoxantrone—hematologic cancer	0.00384	0.014	CbGbCtD
Methotrexate—SLC22A8—Mercaptopurine—hematologic cancer	0.0038	0.0139	CbGbCtD
Methotrexate—ABCG2—Teniposide—hematologic cancer	0.00367	0.0134	CbGbCtD
Methotrexate—ABCG2—Cladribine—hematologic cancer	0.00352	0.0129	CbGbCtD
Methotrexate—ABCG2—Imatinib—hematologic cancer	0.00324	0.0118	CbGbCtD
Methotrexate—ABCC1—Epirubicin—hematologic cancer	0.00311	0.0113	CbGbCtD
Methotrexate—ABCC1—Irinotecan—hematologic cancer	0.00302	0.011	CbGbCtD
Methotrexate—SLCO1A2—Prednisolone—hematologic cancer	0.00301	0.011	CbGbCtD
Methotrexate—ABCG2—Nilotinib—hematologic cancer	0.00294	0.0107	CbGbCtD
Methotrexate—SLCO1A2—Prednisone—hematologic cancer	0.00285	0.0104	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—hematologic cancer	0.00269	0.00981	CbGbCtD
Methotrexate—ABCC1—Vinblastine—hematologic cancer	0.00269	0.00981	CbGbCtD
Methotrexate—ABCC1—Vincristine—hematologic cancer	0.00264	0.00964	CbGbCtD
Methotrexate—ABCG2—Dasatinib—hematologic cancer	0.0026	0.00949	CbGbCtD
Methotrexate—ABCB1—Lenalidomide—hematologic cancer	0.0026	0.00949	CbGbCtD
Methotrexate—ABCG2—Mitoxantrone—hematologic cancer	0.00257	0.00937	CbGbCtD
Methotrexate—SLCO1B1—Irinotecan—hematologic cancer	0.00254	0.00929	CbGbCtD
Methotrexate—ABCC1—Etoposide—hematologic cancer	0.00242	0.00883	CbGbCtD
Methotrexate—ABCC2—Irinotecan—hematologic cancer	0.00224	0.00816	CbGbCtD
Methotrexate—ALB—Imatinib—hematologic cancer	0.00223	0.00815	CbGbCtD
Methotrexate—ABCG2—Irinotecan—hematologic cancer	0.00202	0.00738	CbGbCtD
Methotrexate—ABCC2—Vinblastine—hematologic cancer	0.00199	0.00726	CbGbCtD
Methotrexate—ABCC2—Vincristine—hematologic cancer	0.00195	0.00714	CbGbCtD
Methotrexate—ABCC2—Cisplatin—hematologic cancer	0.00182	0.00666	CbGbCtD
Methotrexate—ABCC2—Etoposide—hematologic cancer	0.00179	0.00654	CbGbCtD
Methotrexate—SLCO1A2—Dexamethasone—hematologic cancer	0.00178	0.00648	CbGbCtD
Methotrexate—ABCG2—Vincristine—hematologic cancer	0.00177	0.00645	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—hematologic cancer	0.00165	0.00603	CbGbCtD
Methotrexate—ABCG2—Cisplatin—hematologic cancer	0.00165	0.00602	CbGbCtD
Methotrexate—ABCG2—Etoposide—hematologic cancer	0.00162	0.00591	CbGbCtD
Methotrexate—ABCB1—Daunorubicin—hematologic cancer	0.00152	0.00556	CbGbCtD
Methotrexate—ABCB1—Alitretinoin—hematologic cancer	0.00149	0.00545	CbGbCtD
Methotrexate—ABCC2—Dexamethasone—hematologic cancer	0.00147	0.00538	CbGbCtD
Methotrexate—ALB—Prednisone—hematologic cancer	0.00147	0.00537	CbGbCtD
Methotrexate—ALB—Irinotecan—hematologic cancer	0.00139	0.00509	CbGbCtD
Methotrexate—ABCG2—Dexamethasone—hematologic cancer	0.00133	0.00486	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—hematologic cancer	0.00122	0.00446	CbGbCtD
Methotrexate—ABCB1—Imatinib—hematologic cancer	0.00117	0.00426	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—hematologic cancer	0.0011	0.00403	CbGbCtD
Methotrexate—ABCB1—Nilotinib—hematologic cancer	0.00106	0.00387	CbGbCtD
Methotrexate—ABCB1—Vinorelbine—hematologic cancer	0.00105	0.00384	CbGbCtD
Methotrexate—FOLR1—hematopoietic system—hematologic cancer	0.000983	0.0298	CbGeAlD
Methotrexate—ABCB1—Dasatinib—hematologic cancer	0.000937	0.00342	CbGbCtD
Methotrexate—ABCB1—Mitoxantrone—hematologic cancer	0.000926	0.00338	CbGbCtD
Methotrexate—Tetrahydrofolic acid—FTCD—hematologic cancer	0.000888	0.389	CrCbGaD
Methotrexate—SLC19A1—hematopoietic system—hematologic cancer	0.000862	0.0261	CbGeAlD
Methotrexate—ABCB1—Betamethasone—hematologic cancer	0.000825	0.00301	CbGbCtD
Methotrexate—ABCB1—Gemcitabine—hematologic cancer	0.000818	0.00299	CbGbCtD
Methotrexate—ABCB1—Prednisolone—hematologic cancer	0.000814	0.00297	CbGbCtD
Methotrexate—ABCB1—Prednisone—hematologic cancer	0.000769	0.00281	CbGbCtD
Methotrexate—ABCB1—Irinotecan—hematologic cancer	0.000729	0.00266	CbGbCtD
Methotrexate—ABCC11—gonad—hematologic cancer	0.000717	0.0217	CbGeAlD
Methotrexate—SLC46A1—hematopoietic system—hematologic cancer	0.000664	0.0201	CbGeAlD
Methotrexate—SLC19A1—gonad—hematologic cancer	0.000655	0.0199	CbGeAlD
Methotrexate—FOLR1—blood—hematologic cancer	0.000651	0.0198	CbGeAlD
Methotrexate—ABCB1—Vinblastine—hematologic cancer	0.000648	0.00237	CbGbCtD
Methotrexate—ABCB1—Vincristine—hematologic cancer	0.000637	0.00233	CbGbCtD
Methotrexate—ABCB1—Cisplatin—hematologic cancer	0.000594	0.00217	CbGbCtD
Methotrexate—ABCB1—Etoposide—hematologic cancer	0.000584	0.00213	CbGbCtD
Methotrexate—FPGS—hematopoietic system—hematologic cancer	0.000574	0.0174	CbGeAlD
Methotrexate—SLC19A1—blood—hematologic cancer	0.000571	0.0173	CbGeAlD
Methotrexate—FOLR1—lung—hematologic cancer	0.000571	0.0173	CbGeAlD
Methotrexate—ATIC—hematopoietic system—hematologic cancer	0.000555	0.0168	CbGeAlD
Methotrexate—ABCC11—testis—hematologic cancer	0.000516	0.0157	CbGeAlD
Methotrexate—SLC19A1—lung—hematologic cancer	0.000501	0.0152	CbGeAlD
Methotrexate—GGH—gonad—hematologic cancer	0.000497	0.0151	CbGeAlD
Methotrexate—ABCB1—Dexamethasone—hematologic cancer	0.00048	0.00175	CbGbCtD
Methotrexate—SLC19A1—testis—hematologic cancer	0.000472	0.0143	CbGeAlD
Methotrexate—GGH—blood—hematologic cancer	0.000433	0.0131	CbGeAlD
Methotrexate—ATIC—gonad—hematologic cancer	0.000422	0.0128	CbGeAlD
Methotrexate—Pemetrexed—DCK—hematologic cancer	0.000422	0.185	CrCbGaD
Methotrexate—GGH—bone marrow—hematologic cancer	0.000419	0.0127	CbGeAlD
Methotrexate—MTHFR—hematopoietic system—hematologic cancer	0.000413	0.0125	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—hematologic cancer	0.000398	0.00145	CbGbCtD
Methotrexate—SLCO4C1—blood—hematologic cancer	0.000384	0.0116	CbGeAlD
Methotrexate—FPGS—blood—hematologic cancer	0.00038	0.0115	CbGeAlD
Methotrexate—GGH—lung—hematologic cancer	0.000379	0.0115	CbGeAlD
Methotrexate—TYMS—hematopoietic system—hematologic cancer	0.000377	0.0114	CbGeAlD
Methotrexate—DHFR—hematopoietic system—hematologic cancer	0.000373	0.0113	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—hematologic cancer	0.000371	0.0113	CbGeAlD
Methotrexate—ATIC—blood—hematologic cancer	0.000368	0.0112	CbGeAlD
Methotrexate—SLC46A1—testis—hematologic cancer	0.000364	0.011	CbGeAlD
Methotrexate—PGD—hematopoietic system—hematologic cancer	0.000359	0.0109	CbGeAlD
Methotrexate—GGH—testis—hematologic cancer	0.000358	0.0109	CbGeAlD
Methotrexate—SLC19A1—lymph node—hematologic cancer	0.000342	0.0104	CbGeAlD
Methotrexate—SLCO4C1—lung—hematologic cancer	0.000336	0.0102	CbGeAlD
Methotrexate—SLC16A1—hematopoietic system—hematologic cancer	0.000335	0.0102	CbGeAlD
Methotrexate—FPGS—lung—hematologic cancer	0.000334	0.0101	CbGeAlD
Methotrexate—SLCO1B3—lung—hematologic cancer	0.000327	0.00992	CbGeAlD
Methotrexate—SLCO1B1—hematopoietic system—hematologic cancer	0.000326	0.00988	CbGeAlD
Methotrexate—ATIC—lung—hematologic cancer	0.000323	0.00979	CbGeAlD
Methotrexate—FPGS—testis—hematologic cancer	0.000315	0.00955	CbGeAlD
Methotrexate—ABCC3—hematopoietic system—hematologic cancer	0.000309	0.00937	CbGeAlD
Methotrexate—SLCO3A1—gonad—hematologic cancer	0.000309	0.00937	CbGeAlD
Methotrexate—ABCC10—hematopoietic system—hematologic cancer	0.000307	0.00933	CbGeAlD
Methotrexate—ATIC—testis—hematologic cancer	0.000304	0.00923	CbGeAlD
Methotrexate—Tetrahydrofolic acid—MTR—hematologic cancer	0.000293	0.128	CrCbGaD
Methotrexate—TYMS—gonad—hematologic cancer	0.000286	0.00869	CbGeAlD
Methotrexate—DHFR—gonad—hematologic cancer	0.000284	0.0086	CbGeAlD
Methotrexate—MTHFR—blood—hematologic cancer	0.000273	0.0083	CbGeAlD
Methotrexate—PGD—gonad—hematologic cancer	0.000273	0.00827	CbGeAlD
Methotrexate—SLCO3A1—blood—hematologic cancer	0.000269	0.00816	CbGeAlD
Methotrexate—SLCO1A2—hematopoietic system—hematologic cancer	0.000265	0.00804	CbGeAlD
Methotrexate—SLC46A1—lymph node—hematologic cancer	0.000264	0.008	CbGeAlD
Methotrexate—GGH—lymph node—hematologic cancer	0.000259	0.00787	CbGeAlD
Methotrexate—ABCC4—hematopoietic system—hematologic cancer	0.000255	0.00774	CbGeAlD
Methotrexate—SLC16A1—gonad—hematologic cancer	0.000255	0.00772	CbGeAlD
Methotrexate—SLCO1C1—testis—hematologic cancer	0.000253	0.00768	CbGeAlD
Methotrexate—SLC22A8—hematopoietic system—hematologic cancer	0.000253	0.00768	CbGeAlD
Methotrexate—TYMS—blood—hematologic cancer	0.00025	0.00757	CbGeAlD
Methotrexate—DHFR—blood—hematologic cancer	0.000247	0.0075	CbGeAlD
Methotrexate—Leucovorin—ABCC3—hematologic cancer	0.000245	0.107	CrCbGaD
Methotrexate—TYMS—bone marrow—hematologic cancer	0.000241	0.00733	CbGeAlD
Methotrexate—AOX1—gonad—hematologic cancer	0.00024	0.00729	CbGeAlD
Methotrexate—SLC22A7—testis—hematologic cancer	0.00024	0.00728	CbGeAlD
Methotrexate—MTHFR—lung—hematologic cancer	0.00024	0.00727	CbGeAlD
Methotrexate—DHFR—bone marrow—hematologic cancer	0.000239	0.00725	CbGeAlD
Methotrexate—PGD—blood—hematologic cancer	0.000238	0.00721	CbGeAlD
Methotrexate—SLCO3A1—lung—hematologic cancer	0.000236	0.00716	CbGeAlD
Methotrexate—ABCC10—gonad—hematologic cancer	0.000234	0.00709	CbGeAlD
Methotrexate—PGD—bone marrow—hematologic cancer	0.00023	0.00697	CbGeAlD
Methotrexate—FPGS—lymph node—hematologic cancer	0.000228	0.00692	CbGeAlD
Methotrexate—MTHFR—testis—hematologic cancer	0.000226	0.00686	CbGeAlD
Methotrexate—SLCO3A1—testis—hematologic cancer	0.000223	0.00675	CbGeAlD
Methotrexate—ATIC—lymph node—hematologic cancer	0.000221	0.00669	CbGeAlD
Methotrexate—TYMS—lung—hematologic cancer	0.000219	0.00664	CbGeAlD
Methotrexate—DHFR—lung—hematologic cancer	0.000217	0.00657	CbGeAlD
Methotrexate—SLCO1B1—blood—hematologic cancer	0.000216	0.00654	CbGeAlD
Methotrexate—PGD—lung—hematologic cancer	0.000208	0.00632	CbGeAlD
Methotrexate—TYMS—testis—hematologic cancer	0.000206	0.00626	CbGeAlD
Methotrexate—ABCC3—blood—hematologic cancer	0.000205	0.00621	CbGeAlD
Methotrexate—DHFR—testis—hematologic cancer	0.000204	0.0062	CbGeAlD
Methotrexate—ABCC10—blood—hematologic cancer	0.000204	0.00618	CbGeAlD
Methotrexate—ABCC10—bone marrow—hematologic cancer	0.000197	0.00598	CbGeAlD
Methotrexate—PGD—testis—hematologic cancer	0.000196	0.00596	CbGeAlD
Methotrexate—SLC16A1—lung—hematologic cancer	0.000194	0.0059	CbGeAlD
Methotrexate—AOX1—lung—hematologic cancer	0.000183	0.00557	CbGeAlD
Methotrexate—SLC16A1—testis—hematologic cancer	0.000183	0.00556	CbGeAlD
Methotrexate—SLCO1C1—lymph node—hematologic cancer	0.000183	0.00556	CbGeAlD
Methotrexate—TYMS—Nilotinib—Imatinib—hematologic cancer	0.000183	0.139	CbGdCrCtD
Methotrexate—ABCC3—lung—hematologic cancer	0.000179	0.00544	CbGeAlD
Methotrexate—ABCC10—lung—hematologic cancer	0.000179	0.00542	CbGeAlD
Methotrexate—AOX1—testis—hematologic cancer	0.000173	0.00525	CbGeAlD
Methotrexate—ABCC3—testis—hematologic cancer	0.000169	0.00514	CbGeAlD
Methotrexate—ABCC4—blood—hematologic cancer	0.000169	0.00513	CbGeAlD
Methotrexate—ABCC10—testis—hematologic cancer	0.000168	0.00511	CbGeAlD
Methotrexate—SLC22A8—blood—hematologic cancer	0.000168	0.00509	CbGeAlD
Methotrexate—MTHFR—lymph node—hematologic cancer	0.000164	0.00497	CbGeAlD
Methotrexate—ABCC2—blood—hematologic cancer	0.000164	0.00496	CbGeAlD
Methotrexate—ABCC4—bone marrow—hematologic cancer	0.000163	0.00496	CbGeAlD
Methotrexate—SLCO3A1—lymph node—hematologic cancer	0.000161	0.00489	CbGeAlD
Methotrexate—Folic Acid—ABCC3—hematologic cancer	0.000158	0.0692	CrCbGaD
Methotrexate—SLCO1A2—lung—hematologic cancer	0.000154	0.00467	CbGeAlD
Methotrexate—TYMS—lymph node—hematologic cancer	0.00015	0.00454	CbGeAlD
Methotrexate—DHFR—lymph node—hematologic cancer	0.000148	0.00449	CbGeAlD
Methotrexate—ABCC4—lung—hematologic cancer	0.000148	0.00449	CbGeAlD
Methotrexate—SLCO1A2—testis—hematologic cancer	0.000145	0.00441	CbGeAlD
Methotrexate—ALB—testis—hematologic cancer	0.000144	0.00438	CbGeAlD
Methotrexate—ABCC1—blood—hematologic cancer	0.000144	0.00437	CbGeAlD
Methotrexate—PGD—lymph node—hematologic cancer	0.000142	0.00432	CbGeAlD
Methotrexate—ABCC4—testis—hematologic cancer	0.00014	0.00424	CbGeAlD
Methotrexate—ABCC2—testis—hematologic cancer	0.000135	0.0041	CbGeAlD
Methotrexate—SLC16A1—lymph node—hematologic cancer	0.000133	0.00403	CbGeAlD
Methotrexate—ABCC1—lung—hematologic cancer	0.000126	0.00383	CbGeAlD
Methotrexate—AOX1—lymph node—hematologic cancer	0.000125	0.00381	CbGeAlD
Methotrexate—ABCC3—lymph node—hematologic cancer	0.000123	0.00372	CbGeAlD
Methotrexate—ABCC10—lymph node—hematologic cancer	0.000122	0.0037	CbGeAlD
Methotrexate—ABCG2—blood—hematologic cancer	0.000119	0.00362	CbGeAlD
Methotrexate—ABCC1—testis—hematologic cancer	0.000119	0.00362	CbGeAlD
Methotrexate—ABCG2—bone marrow—hematologic cancer	0.000115	0.0035	CbGeAlD
Methotrexate—TYMS—Vitamin A—Alitretinoin—hematologic cancer	0.00011	0.0837	CbGdCrCtD
Methotrexate—ALB—lymph node—hematologic cancer	0.000105	0.00317	CbGeAlD
Methotrexate—ABCG2—lung—hematologic cancer	0.000105	0.00317	CbGeAlD
Methotrexate—ABCC4—lymph node—hematologic cancer	0.000101	0.00307	CbGeAlD
Methotrexate—Folic Acid—MTHFR—hematologic cancer	0.0001	0.0439	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—hematologic cancer	0.0001	0.0439	CrCbGaD
Methotrexate—ABCG2—testis—hematologic cancer	9.87e-05	0.00299	CbGeAlD
Methotrexate—ABCC2—lymph node—hematologic cancer	9.81e-05	0.00297	CbGeAlD
Methotrexate—ABCB1—hematopoietic system—hematologic cancer	8.88e-05	0.00269	CbGeAlD
Methotrexate—ABCC1—lymph node—hematologic cancer	8.64e-05	0.00262	CbGeAlD
Methotrexate—TYMS—Tretinoin—Alitretinoin—hematologic cancer	7.71e-05	0.0585	CbGdCrCtD
Methotrexate—TYMS—Isotretinoin—Alitretinoin—hematologic cancer	7.71e-05	0.0585	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Teniposide—hematologic cancer	7.69e-05	0.0583	CbGdCrCtD
Methotrexate—Folic Acid—ABCG2—hematologic cancer	7.67e-05	0.0336	CrCbGaD
Methotrexate—ABCG2—lymph node—hematologic cancer	7.15e-05	0.00217	CbGeAlD
Methotrexate—ABCB1—gonad—hematologic cancer	6.75e-05	0.00205	CbGeAlD
Methotrexate—ABCB1—blood—hematologic cancer	5.88e-05	0.00178	CbGeAlD
Methotrexate—TYMS—Menadione—Thalidomide—hematologic cancer	5.83e-05	0.0442	CbGdCrCtD
Methotrexate—ABCB1—bone marrow—hematologic cancer	5.69e-05	0.00173	CbGeAlD
Methotrexate—ABCB1—lung—hematologic cancer	5.16e-05	0.00156	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinorelbine—hematologic cancer	4.89e-05	0.0371	CbGdCrCtD
Methotrexate—ABCB1—testis—hematologic cancer	4.86e-05	0.00148	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—hematologic cancer	4.58e-05	0.0347	CbGdCrCtD
Methotrexate—TYMS—Vinorelbine—Vincristine—hematologic cancer	4.58e-05	0.0347	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—hematologic cancer	4.57e-05	0.0347	CbGdCrCtD
Methotrexate—TYMS—Vinblastine—Vinorelbine—hematologic cancer	3.94e-05	0.0299	CbGdCrCtD
Methotrexate—TYMS—Vincristine—Vinblastine—hematologic cancer	3.91e-05	0.0297	CbGdCrCtD
Methotrexate—ABCB1—lymph node—hematologic cancer	3.53e-05	0.00107	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vincristine—hematologic cancer	3.15e-05	0.0239	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Pentostatin—hematologic cancer	2.98e-05	0.0226	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Clofarabine—hematologic cancer	2.66e-05	0.0202	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Nelarabine—hematologic cancer	2.5e-05	0.019	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Fludarabine—hematologic cancer	1.95e-05	0.0148	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Gemcitabine—hematologic cancer	1.84e-05	0.014	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Cytarabine—hematologic cancer	1.84e-05	0.014	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Cladribine—hematologic cancer	1.8e-05	0.0136	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Dexamethasone—hematologic cancer	1.14e-05	0.00861	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Betamethasone—hematologic cancer	1.14e-05	0.00861	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Dexamethasone—hematologic cancer	1.12e-05	0.0085	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Betamethasone—hematologic cancer	1.12e-05	0.0085	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Triamcinolone—hematologic cancer	1.11e-05	0.00842	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Betamethasone—hematologic cancer	1.11e-05	0.00841	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Dexamethasone—hematologic cancer	1.11e-05	0.00841	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Triamcinolone—hematologic cancer	1.09e-05	0.00831	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Dexamethasone—hematologic cancer	1.08e-05	0.00821	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Betamethasone—hematologic cancer	1.08e-05	0.00821	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Triamcinolone—hematologic cancer	1.06e-05	0.00802	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Prednisone—hematologic cancer	1.05e-05	0.00799	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Prednisone—hematologic cancer	1.04e-05	0.00788	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Prednisone—hematologic cancer	1.03e-05	0.0078	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Prednisolone—hematologic cancer	1.03e-05	0.0078	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Dexamethasone—hematologic cancer	1.02e-05	0.00776	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Betamethasone—hematologic cancer	1.02e-05	0.00776	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Prednisolone—hematologic cancer	1.01e-05	0.00769	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Prednisolone—hematologic cancer	1e-05	0.00762	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Triamcinolone—hematologic cancer	9.99e-06	0.00758	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Prednisone—hematologic cancer	9.48e-06	0.00719	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Prednisolone—hematologic cancer	9.25e-06	0.00702	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Betamethasone—hematologic cancer	8.96e-06	0.0068	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Dexamethasone—hematologic cancer	8.96e-06	0.0068	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Triamcinolone—hematologic cancer	8.76e-06	0.00664	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Prednisone—hematologic cancer	8.31e-06	0.0063	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Prednisolone—hematologic cancer	8.11e-06	0.00615	CbGdCrCtD
Methotrexate—TYMS—Danazol—Prednisone—hematologic cancer	7.96e-06	0.00604	CbGdCrCtD
Methotrexate—Dermatitis—Mitoxantrone—hematologic cancer	5.01e-06	4.33e-05	CcSEcCtD
Methotrexate—Dermatitis—Irinotecan—hematologic cancer	5.01e-06	4.33e-05	CcSEcCtD
Methotrexate—Headache—Mitoxantrone—hematologic cancer	4.98e-06	4.3e-05	CcSEcCtD
Methotrexate—Headache—Irinotecan—hematologic cancer	4.98e-06	4.3e-05	CcSEcCtD
Methotrexate—Nausea—Ifosfamide—hematologic cancer	4.97e-06	4.3e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.96e-06	4.28e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.96e-06	4.28e-05	CcSEcCtD
Methotrexate—Arthralgia—Prednisone—hematologic cancer	4.94e-06	4.27e-05	CcSEcCtD
Methotrexate—Myalgia—Prednisone—hematologic cancer	4.94e-06	4.27e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Triamcinolone—hematologic cancer	4.94e-06	4.27e-05	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—hematologic cancer	4.94e-06	4.27e-05	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—hematologic cancer	4.93e-06	4.26e-05	CcSEcCtD
Methotrexate—Vomiting—Gemcitabine—hematologic cancer	4.92e-06	4.25e-05	CcSEcCtD
Methotrexate—Insomnia—Dexamethasone—hematologic cancer	4.92e-06	4.25e-05	CcSEcCtD
Methotrexate—Insomnia—Betamethasone—hematologic cancer	4.92e-06	4.25e-05	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.91e-06	4.24e-05	CcSEcCtD
Methotrexate—Paraesthesia—Betamethasone—hematologic cancer	4.89e-06	4.22e-05	CcSEcCtD
Methotrexate—Paraesthesia—Dexamethasone—hematologic cancer	4.89e-06	4.22e-05	CcSEcCtD
Methotrexate—Discomfort—Prednisone—hematologic cancer	4.88e-06	4.22e-05	CcSEcCtD
Methotrexate—Rash—Gemcitabine—hematologic cancer	4.88e-06	4.22e-05	CcSEcCtD
Methotrexate—Dermatitis—Gemcitabine—hematologic cancer	4.88e-06	4.21e-05	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—hematologic cancer	4.88e-06	4.21e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—hematologic cancer	4.87e-06	4.21e-05	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—hematologic cancer	4.86e-06	4.2e-05	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—hematologic cancer	4.85e-06	4.19e-05	CcSEcCtD
Methotrexate—Headache—Gemcitabine—hematologic cancer	4.85e-06	4.19e-05	CcSEcCtD
Methotrexate—Nausea—Vincristine—hematologic cancer	4.85e-06	4.19e-05	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—hematologic cancer	4.84e-06	4.18e-05	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—hematologic cancer	4.83e-06	4.17e-05	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—hematologic cancer	4.83e-06	4.17e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Prednisolone—hematologic cancer	4.81e-06	4.15e-05	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—hematologic cancer	4.79e-06	4.14e-05	CcSEcCtD
Methotrexate—Dyspepsia—Betamethasone—hematologic cancer	4.79e-06	4.14e-05	CcSEcCtD
Methotrexate—Dyspepsia—Dexamethasone—hematologic cancer	4.79e-06	4.14e-05	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—hematologic cancer	4.77e-06	4.12e-05	CcSEcCtD
Methotrexate—Urticaria—Triamcinolone—hematologic cancer	4.76e-06	4.12e-05	CcSEcCtD
Methotrexate—Asthenia—Etoposide—hematologic cancer	4.74e-06	4.1e-05	CcSEcCtD
Methotrexate—Body temperature increased—Triamcinolone—hematologic cancer	4.74e-06	4.1e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisone—hematologic cancer	4.74e-06	4.09e-05	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—hematologic cancer	4.73e-06	4.09e-05	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—hematologic cancer	4.73e-06	4.09e-05	CcSEcCtD
Methotrexate—Decreased appetite—Betamethasone—hematologic cancer	4.73e-06	4.09e-05	CcSEcCtD
Methotrexate—Decreased appetite—Dexamethasone—hematologic cancer	4.73e-06	4.09e-05	CcSEcCtD
Methotrexate—Nausea—Mitoxantrone—hematologic cancer	4.72e-06	4.08e-05	CcSEcCtD
Methotrexate—Nausea—Irinotecan—hematologic cancer	4.72e-06	4.08e-05	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—hematologic cancer	4.71e-06	4.07e-05	CcSEcCtD
Methotrexate—Infection—Prednisone—hematologic cancer	4.71e-06	4.07e-05	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—hematologic cancer	4.7e-06	4.06e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.7e-06	4.06e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.7e-06	4.06e-05	CcSEcCtD
Methotrexate—Fatigue—Betamethasone—hematologic cancer	4.69e-06	4.05e-05	CcSEcCtD
Methotrexate—Fatigue—Dexamethasone—hematologic cancer	4.69e-06	4.05e-05	CcSEcCtD
Methotrexate—Chills—Epirubicin—hematologic cancer	4.68e-06	4.04e-05	CcSEcCtD
Methotrexate—Pruritus—Etoposide—hematologic cancer	4.68e-06	4.04e-05	CcSEcCtD
Methotrexate—Pain—Betamethasone—hematologic cancer	4.65e-06	4.02e-05	CcSEcCtD
Methotrexate—Pain—Dexamethasone—hematologic cancer	4.65e-06	4.02e-05	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—hematologic cancer	4.65e-06	4.02e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Prednisone—hematologic cancer	4.65e-06	4.01e-05	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—hematologic cancer	4.61e-06	3.98e-05	CcSEcCtD
Methotrexate—Skin disorder—Prednisone—hematologic cancer	4.6e-06	3.98e-05	CcSEcCtD
Methotrexate—Nausea—Gemcitabine—hematologic cancer	4.6e-06	3.97e-05	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—hematologic cancer	4.59e-06	3.96e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Prednisone—hematologic cancer	4.58e-06	3.96e-05	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—hematologic cancer	4.57e-06	3.95e-05	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—hematologic cancer	4.56e-06	3.94e-05	CcSEcCtD
Methotrexate—Rash—Cisplatin—hematologic cancer	4.55e-06	3.93e-05	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—hematologic cancer	4.55e-06	3.93e-05	CcSEcCtD
Methotrexate—Erythema—Epirubicin—hematologic cancer	4.54e-06	3.92e-05	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—hematologic cancer	4.54e-06	3.92e-05	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—hematologic cancer	4.52e-06	3.91e-05	CcSEcCtD
Methotrexate—Anorexia—Prednisone—hematologic cancer	4.52e-06	3.9e-05	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—hematologic cancer	4.51e-06	3.9e-05	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—hematologic cancer	4.5e-06	3.89e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Dexamethasone—hematologic cancer	4.48e-06	3.87e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Betamethasone—hematologic cancer	4.48e-06	3.87e-05	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—hematologic cancer	4.48e-06	3.87e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Betamethasone—hematologic cancer	4.45e-06	3.84e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.45e-06	3.84e-05	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—hematologic cancer	4.45e-06	3.84e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Triamcinolone—hematologic cancer	4.42e-06	3.82e-05	CcSEcCtD
Methotrexate—Back pain—Epirubicin—hematologic cancer	4.39e-06	3.79e-05	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—hematologic cancer	4.38e-06	3.78e-05	CcSEcCtD
Methotrexate—Dizziness—Etoposide—hematologic cancer	4.37e-06	3.78e-05	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—hematologic cancer	4.36e-06	3.77e-05	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—hematologic cancer	4.35e-06	3.76e-05	CcSEcCtD
Methotrexate—Chills—Doxorubicin—hematologic cancer	4.33e-06	3.74e-05	CcSEcCtD
Methotrexate—Urticaria—Betamethasone—hematologic cancer	4.32e-06	3.73e-05	CcSEcCtD
Methotrexate—Urticaria—Dexamethasone—hematologic cancer	4.32e-06	3.73e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.32e-06	3.73e-05	CcSEcCtD
Methotrexate—Dizziness—Prednisolone—hematologic cancer	4.31e-06	3.73e-05	CcSEcCtD
Methotrexate—Asthenia—Triamcinolone—hematologic cancer	4.3e-06	3.72e-05	CcSEcCtD
Methotrexate—Body temperature increased—Betamethasone—hematologic cancer	4.3e-06	3.72e-05	CcSEcCtD
Methotrexate—Abdominal pain—Betamethasone—hematologic cancer	4.3e-06	3.72e-05	CcSEcCtD
Methotrexate—Body temperature increased—Dexamethasone—hematologic cancer	4.3e-06	3.72e-05	CcSEcCtD
Methotrexate—Abdominal pain—Dexamethasone—hematologic cancer	4.3e-06	3.72e-05	CcSEcCtD
Methotrexate—Nausea—Cisplatin—hematologic cancer	4.29e-06	3.7e-05	CcSEcCtD
Methotrexate—Insomnia—Prednisone—hematologic cancer	4.29e-06	3.7e-05	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—hematologic cancer	4.28e-06	3.7e-05	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—hematologic cancer	4.27e-06	3.68e-05	CcSEcCtD
Methotrexate—Paraesthesia—Prednisone—hematologic cancer	4.26e-06	3.68e-05	CcSEcCtD
Methotrexate—Pruritus—Triamcinolone—hematologic cancer	4.24e-06	3.67e-05	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—hematologic cancer	4.23e-06	3.65e-05	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—hematologic cancer	4.21e-06	3.64e-05	CcSEcCtD
Methotrexate—Vomiting—Etoposide—hematologic cancer	4.2e-06	3.63e-05	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—hematologic cancer	4.2e-06	3.63e-05	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—hematologic cancer	4.2e-06	3.63e-05	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—hematologic cancer	4.2e-06	3.63e-05	CcSEcCtD
Methotrexate—Dyspepsia—Prednisone—hematologic cancer	4.17e-06	3.6e-05	CcSEcCtD
Methotrexate—Rash—Etoposide—hematologic cancer	4.17e-06	3.6e-05	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—hematologic cancer	4.17e-06	3.6e-05	CcSEcCtD
Methotrexate—Headache—Etoposide—hematologic cancer	4.14e-06	3.58e-05	CcSEcCtD
Methotrexate—Decreased appetite—Prednisone—hematologic cancer	4.12e-06	3.56e-05	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—hematologic cancer	4.12e-06	3.55e-05	CcSEcCtD
Methotrexate—Rash—Prednisolone—hematologic cancer	4.11e-06	3.55e-05	CcSEcCtD
Methotrexate—Dermatitis—Prednisolone—hematologic cancer	4.11e-06	3.55e-05	CcSEcCtD
Methotrexate—Malaise—Epirubicin—hematologic cancer	4.1e-06	3.54e-05	CcSEcCtD
Methotrexate—Fatigue—Prednisone—hematologic cancer	4.09e-06	3.53e-05	CcSEcCtD
Methotrexate—Headache—Prednisolone—hematologic cancer	4.09e-06	3.53e-05	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—hematologic cancer	4.08e-06	3.52e-05	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—hematologic cancer	4.07e-06	3.51e-05	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—hematologic cancer	4.06e-06	3.51e-05	CcSEcCtD
Methotrexate—Dizziness—Triamcinolone—hematologic cancer	3.97e-06	3.43e-05	CcSEcCtD
Methotrexate—Cough—Epirubicin—hematologic cancer	3.96e-06	3.42e-05	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—hematologic cancer	3.96e-06	3.42e-05	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—hematologic cancer	3.93e-06	3.4e-05	CcSEcCtD
Methotrexate—Nausea—Etoposide—hematologic cancer	3.93e-06	3.39e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Prednisone—hematologic cancer	3.91e-06	3.37e-05	CcSEcCtD
Methotrexate—Asthenia—Betamethasone—hematologic cancer	3.9e-06	3.37e-05	CcSEcCtD
Methotrexate—Asthenia—Dexamethasone—hematologic cancer	3.9e-06	3.37e-05	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—hematologic cancer	3.9e-06	3.37e-05	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—hematologic cancer	3.88e-06	3.36e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Prednisone—hematologic cancer	3.88e-06	3.35e-05	CcSEcCtD
Methotrexate—Nausea—Prednisolone—hematologic cancer	3.87e-06	3.35e-05	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—hematologic cancer	3.87e-06	3.34e-05	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—hematologic cancer	3.87e-06	3.34e-05	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—hematologic cancer	3.87e-06	3.34e-05	CcSEcCtD
Methotrexate—Pruritus—Betamethasone—hematologic cancer	3.85e-06	3.33e-05	CcSEcCtD
Methotrexate—Pruritus—Dexamethasone—hematologic cancer	3.85e-06	3.33e-05	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.84e-06	3.32e-05	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—hematologic cancer	3.82e-06	3.3e-05	CcSEcCtD
Methotrexate—Vomiting—Triamcinolone—hematologic cancer	3.81e-06	3.29e-05	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—hematologic cancer	3.79e-06	3.27e-05	CcSEcCtD
Methotrexate—Rash—Triamcinolone—hematologic cancer	3.78e-06	3.27e-05	CcSEcCtD
Methotrexate—Dermatitis—Triamcinolone—hematologic cancer	3.78e-06	3.26e-05	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—hematologic cancer	3.78e-06	3.26e-05	CcSEcCtD
Methotrexate—Urticaria—Prednisone—hematologic cancer	3.76e-06	3.25e-05	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—hematologic cancer	3.76e-06	3.25e-05	CcSEcCtD
Methotrexate—Headache—Triamcinolone—hematologic cancer	3.76e-06	3.25e-05	CcSEcCtD
Methotrexate—Abdominal pain—Prednisone—hematologic cancer	3.75e-06	3.24e-05	CcSEcCtD
Methotrexate—Body temperature increased—Prednisone—hematologic cancer	3.75e-06	3.24e-05	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—hematologic cancer	3.74e-06	3.23e-05	CcSEcCtD
Methotrexate—Diarrhoea—Betamethasone—hematologic cancer	3.72e-06	3.22e-05	CcSEcCtD
Methotrexate—Diarrhoea—Dexamethasone—hematologic cancer	3.72e-06	3.22e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—hematologic cancer	3.71e-06	3.2e-05	CcSEcCtD
Methotrexate—Infection—Epirubicin—hematologic cancer	3.68e-06	3.18e-05	CcSEcCtD
Methotrexate—Cough—Doxorubicin—hematologic cancer	3.67e-06	3.17e-05	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—hematologic cancer	3.64e-06	3.15e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—hematologic cancer	3.63e-06	3.14e-05	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—hematologic cancer	3.63e-06	3.13e-05	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—hematologic cancer	3.6e-06	3.11e-05	CcSEcCtD
Methotrexate—Dizziness—Dexamethasone—hematologic cancer	3.6e-06	3.11e-05	CcSEcCtD
Methotrexate—Dizziness—Betamethasone—hematologic cancer	3.6e-06	3.11e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—hematologic cancer	3.58e-06	3.1e-05	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—hematologic cancer	3.58e-06	3.09e-05	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—hematologic cancer	3.58e-06	3.09e-05	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—hematologic cancer	3.58e-06	3.09e-05	CcSEcCtD
Methotrexate—Nausea—Triamcinolone—hematologic cancer	3.56e-06	3.08e-05	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.55e-06	3.07e-05	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—hematologic cancer	3.53e-06	3.05e-05	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—hematologic cancer	3.53e-06	3.05e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Prednisone—hematologic cancer	3.49e-06	3.02e-05	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—hematologic cancer	3.46e-06	2.99e-05	CcSEcCtD
Methotrexate—Vomiting—Dexamethasone—hematologic cancer	3.46e-06	2.99e-05	CcSEcCtD
Methotrexate—Vomiting—Betamethasone—hematologic cancer	3.46e-06	2.99e-05	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—hematologic cancer	3.46e-06	2.99e-05	CcSEcCtD
Methotrexate—Rash—Betamethasone—hematologic cancer	3.43e-06	2.96e-05	CcSEcCtD
Methotrexate—Rash—Dexamethasone—hematologic cancer	3.43e-06	2.96e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—hematologic cancer	3.43e-06	2.96e-05	CcSEcCtD
Methotrexate—Dermatitis—Betamethasone—hematologic cancer	3.43e-06	2.96e-05	CcSEcCtD
Methotrexate—Dermatitis—Dexamethasone—hematologic cancer	3.43e-06	2.96e-05	CcSEcCtD
Methotrexate—Headache—Dexamethasone—hematologic cancer	3.41e-06	2.94e-05	CcSEcCtD
Methotrexate—Headache—Betamethasone—hematologic cancer	3.41e-06	2.94e-05	CcSEcCtD
Methotrexate—Infection—Doxorubicin—hematologic cancer	3.41e-06	2.94e-05	CcSEcCtD
Methotrexate—Asthenia—Prednisone—hematologic cancer	3.4e-06	2.94e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.38e-06	2.92e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—hematologic cancer	3.36e-06	2.91e-05	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—hematologic cancer	3.36e-06	2.9e-05	CcSEcCtD
Methotrexate—Pruritus—Prednisone—hematologic cancer	3.35e-06	2.9e-05	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—hematologic cancer	3.35e-06	2.9e-05	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—hematologic cancer	3.33e-06	2.88e-05	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—hematologic cancer	3.33e-06	2.88e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—hematologic cancer	3.32e-06	2.86e-05	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—hematologic cancer	3.3e-06	2.85e-05	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—hematologic cancer	3.3e-06	2.85e-05	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—hematologic cancer	3.27e-06	2.82e-05	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—hematologic cancer	3.26e-06	2.82e-05	CcSEcCtD
Methotrexate—Diarrhoea—Prednisone—hematologic cancer	3.24e-06	2.8e-05	CcSEcCtD
Methotrexate—Nausea—Betamethasone—hematologic cancer	3.23e-06	2.79e-05	CcSEcCtD
Methotrexate—Nausea—Dexamethasone—hematologic cancer	3.23e-06	2.79e-05	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—hematologic cancer	3.22e-06	2.78e-05	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—hematologic cancer	3.2e-06	2.77e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.2e-06	2.76e-05	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—hematologic cancer	3.2e-06	2.76e-05	CcSEcCtD
Methotrexate—Pain—Epirubicin—hematologic cancer	3.17e-06	2.74e-05	CcSEcCtD
Methotrexate—Dizziness—Prednisone—hematologic cancer	3.13e-06	2.71e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.12e-06	2.7e-05	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—hematologic cancer	3.1e-06	2.68e-05	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—hematologic cancer	3.08e-06	2.66e-05	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—hematologic cancer	3.06e-06	2.64e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—hematologic cancer	3.05e-06	2.64e-05	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—hematologic cancer	3.05e-06	2.63e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—hematologic cancer	3.03e-06	2.62e-05	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—hematologic cancer	3.02e-06	2.61e-05	CcSEcCtD
Methotrexate—Vomiting—Prednisone—hematologic cancer	3.01e-06	2.6e-05	CcSEcCtD
Methotrexate—Rash—Prednisone—hematologic cancer	2.99e-06	2.58e-05	CcSEcCtD
Methotrexate—Dermatitis—Prednisone—hematologic cancer	2.99e-06	2.58e-05	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—hematologic cancer	2.98e-06	2.58e-05	CcSEcCtD
Methotrexate—Headache—Prednisone—hematologic cancer	2.97e-06	2.56e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.96e-06	2.56e-05	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—hematologic cancer	2.96e-06	2.55e-05	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—hematologic cancer	2.94e-06	2.54e-05	CcSEcCtD
Methotrexate—Pain—Doxorubicin—hematologic cancer	2.93e-06	2.53e-05	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—hematologic cancer	2.93e-06	2.53e-05	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—hematologic cancer	2.93e-06	2.53e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—hematologic cancer	2.83e-06	2.44e-05	CcSEcCtD
Methotrexate—Nausea—Prednisone—hematologic cancer	2.82e-06	2.43e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.8e-06	2.42e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—hematologic cancer	2.73e-06	2.36e-05	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—hematologic cancer	2.72e-06	2.35e-05	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—hematologic cancer	2.71e-06	2.34e-05	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—hematologic cancer	2.71e-06	2.34e-05	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—hematologic cancer	2.66e-06	2.3e-05	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—hematologic cancer	2.62e-06	2.27e-05	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—hematologic cancer	2.54e-06	2.19e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—hematologic cancer	2.53e-06	2.18e-05	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—hematologic cancer	2.46e-06	2.13e-05	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—hematologic cancer	2.45e-06	2.12e-05	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—hematologic cancer	2.43e-06	2.1e-05	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—hematologic cancer	2.36e-06	2.04e-05	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—hematologic cancer	2.35e-06	2.03e-05	CcSEcCtD
Methotrexate—Rash—Epirubicin—hematologic cancer	2.34e-06	2.02e-05	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—hematologic cancer	2.33e-06	2.02e-05	CcSEcCtD
Methotrexate—Headache—Epirubicin—hematologic cancer	2.32e-06	2.01e-05	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—hematologic cancer	2.27e-06	1.96e-05	CcSEcCtD
Methotrexate—Nausea—Epirubicin—hematologic cancer	2.2e-06	1.9e-05	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—hematologic cancer	2.18e-06	1.88e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—hematologic cancer	2.16e-06	1.87e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—hematologic cancer	2.16e-06	1.87e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—hematologic cancer	2.15e-06	1.86e-05	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—hematologic cancer	2.04e-06	1.76e-05	CcSEcCtD
Methotrexate—MTHFR—Disease—TGFB1—hematologic cancer	1.13e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.13e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR3—hematologic cancer	1.13e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ABCC3—hematologic cancer	1.13e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTO1—hematologic cancer	1.13e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TXN—hematologic cancer	1.13e-06	1.94e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—hematologic cancer	1.13e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—hematologic cancer	1.12e-06	1.93e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—hematologic cancer	1.12e-06	1.92e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3R1—hematologic cancer	1.11e-06	1.92e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NCOR1—hematologic cancer	1.11e-06	1.92e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTM1—hematologic cancer	1.11e-06	1.92e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—hematologic cancer	1.11e-06	1.91e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NUP98—hematologic cancer	1.11e-06	1.91e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—hematologic cancer	1.11e-06	1.91e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—hematologic cancer	1.11e-06	1.91e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—hematologic cancer	1.11e-06	1.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SPHK1—hematologic cancer	1.1e-06	1.9e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—hematologic cancer	1.09e-06	1.88e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—EP300—hematologic cancer	1.09e-06	1.88e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—hematologic cancer	1.09e-06	1.87e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—hematologic cancer	1.08e-06	1.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—hematologic cancer	1.08e-06	1.86e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CREBBP—hematologic cancer	1.08e-06	1.86e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADCY7—hematologic cancer	1.08e-06	1.86e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA3—hematologic cancer	1.08e-06	1.86e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—hematologic cancer	1.07e-06	1.85e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BAD—hematologic cancer	1.07e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NUP214—hematologic cancer	1.07e-06	1.84e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—hematologic cancer	1.07e-06	1.84e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—hematologic cancer	1.07e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—hematologic cancer	1.06e-06	1.83e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—hematologic cancer	1.06e-06	1.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—UGT1A1—hematologic cancer	1.06e-06	1.83e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.06e-06	1.82e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	1.06e-06	1.82e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—hematologic cancer	1.05e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCG2—hematologic cancer	1.05e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTR—hematologic cancer	1.05e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD80—hematologic cancer	1.04e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.04e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—hematologic cancer	1.04e-06	1.79e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—hematologic cancer	1.04e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—hematologic cancer	1.03e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CRABP1—hematologic cancer	1.03e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC22A1—hematologic cancer	1.03e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NCOR1—hematologic cancer	1.03e-06	1.77e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—hematologic cancer	1.03e-06	1.77e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—hematologic cancer	1.03e-06	1.77e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CREBBP—hematologic cancer	1.03e-06	1.77e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—hematologic cancer	1.03e-06	1.77e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—hematologic cancer	1.03e-06	1.76e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—hematologic cancer	1.02e-06	1.76e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3R1—hematologic cancer	1.02e-06	1.76e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTPN11—hematologic cancer	1.02e-06	1.76e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—hematologic cancer	1.02e-06	1.75e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.01e-06	1.74e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—hematologic cancer	1.01e-06	1.74e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—hematologic cancer	1.01e-06	1.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALOX5—hematologic cancer	1.01e-06	1.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.01e-06	1.73e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—hematologic cancer	1e-06	1.72e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—hematologic cancer	9.98e-07	1.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREB1—hematologic cancer	9.88e-07	1.7e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—hematologic cancer	9.83e-07	1.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.83e-07	1.69e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—hematologic cancer	9.82e-07	1.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—hematologic cancer	9.76e-07	1.68e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SDC1—hematologic cancer	9.76e-07	1.68e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—hematologic cancer	9.75e-07	1.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NUP98—hematologic cancer	9.74e-07	1.68e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—hematologic cancer	9.7e-07	1.67e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3R1—hematologic cancer	9.67e-07	1.66e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—hematologic cancer	9.66e-07	1.66e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—hematologic cancer	9.64e-07	1.66e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6R—hematologic cancer	9.64e-07	1.66e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—hematologic cancer	9.63e-07	1.66e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREBBP—hematologic cancer	9.63e-07	1.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADCY7—hematologic cancer	9.45e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA3—hematologic cancer	9.45e-07	1.63e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—hematologic cancer	9.42e-07	1.62e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—hematologic cancer	9.42e-07	1.62e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—JAK2—hematologic cancer	9.39e-07	1.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NUP214—hematologic cancer	9.38e-07	1.62e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	9.35e-07	1.61e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—hematologic cancer	9.33e-07	1.61e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.32e-07	1.6e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—hematologic cancer	9.26e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3R1—hematologic cancer	9.21e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ABCG2—hematologic cancer	9.19e-07	1.58e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTR—hematologic cancer	9.19e-07	1.58e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAP2K1—hematologic cancer	9.19e-07	1.58e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—hematologic cancer	9.13e-07	1.57e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.12e-07	1.57e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—hematologic cancer	9.11e-07	1.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—hematologic cancer	9.02e-07	1.55e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CREBBP—hematologic cancer	8.96e-07	1.54e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—hematologic cancer	8.92e-07	1.54e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—hematologic cancer	8.92e-07	1.54e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—hematologic cancer	8.88e-07	1.53e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—hematologic cancer	8.84e-07	1.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.8e-07	1.51e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—hematologic cancer	8.75e-07	1.51e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGF2—hematologic cancer	8.74e-07	1.5e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—hematologic cancer	8.71e-07	1.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—hematologic cancer	8.69e-07	1.5e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.67e-07	1.49e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	8.62e-07	1.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3R1—hematologic cancer	8.62e-07	1.48e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—hematologic cancer	8.57e-07	1.47e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SDC1—hematologic cancer	8.55e-07	1.47e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—hematologic cancer	8.54e-07	1.47e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—hematologic cancer	8.5e-07	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—hematologic cancer	8.49e-07	1.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	8.49e-07	1.46e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—hematologic cancer	8.46e-07	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—hematologic cancer	8.39e-07	1.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—JAK2—hematologic cancer	8.38e-07	1.44e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—hematologic cancer	8.34e-07	1.44e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NQO1—hematologic cancer	8.3e-07	1.43e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CD44—hematologic cancer	8.3e-07	1.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	8.26e-07	1.42e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—hematologic cancer	8.19e-07	1.41e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	8.19e-07	1.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—hematologic cancer	8.18e-07	1.41e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—hematologic cancer	8.14e-07	1.4e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.12e-07	1.4e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—hematologic cancer	8.08e-07	1.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CREBBP—hematologic cancer	8.06e-07	1.39e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3R1—hematologic cancer	8.02e-07	1.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—hematologic cancer	7.96e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—hematologic cancer	7.96e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—hematologic cancer	7.94e-07	1.37e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—hematologic cancer	7.93e-07	1.36e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—hematologic cancer	7.89e-07	1.36e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—hematologic cancer	7.88e-07	1.36e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYCS—hematologic cancer	7.85e-07	1.35e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSP90AA1—hematologic cancer	7.8e-07	1.34e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—hematologic cancer	7.77e-07	1.34e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—hematologic cancer	7.69e-07	1.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	7.66e-07	1.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CREBBP—hematologic cancer	7.66e-07	1.32e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—hematologic cancer	7.65e-07	1.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—hematologic cancer	7.64e-07	1.32e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—hematologic cancer	7.59e-07	1.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—hematologic cancer	7.55e-07	1.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—hematologic cancer	7.47e-07	1.28e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—hematologic cancer	7.4e-07	1.27e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—hematologic cancer	7.35e-07	1.27e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—hematologic cancer	7.35e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NQO1—hematologic cancer	7.27e-07	1.25e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CD44—hematologic cancer	7.27e-07	1.25e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	7.26e-07	1.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3R1—hematologic cancer	7.22e-07	1.24e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—hematologic cancer	7.18e-07	1.24e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—hematologic cancer	7.17e-07	1.23e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—hematologic cancer	7.15e-07	1.23e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CREBBP—hematologic cancer	7.09e-07	1.22e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.02e-07	1.21e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—hematologic cancer	7.01e-07	1.21e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—hematologic cancer	7e-07	1.2e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—hematologic cancer	6.96e-07	1.2e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—hematologic cancer	6.92e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—hematologic cancer	6.89e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—hematologic cancer	6.88e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYCS—hematologic cancer	6.88e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—hematologic cancer	6.87e-07	1.18e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	6.86e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSP90AA1—hematologic cancer	6.83e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—hematologic cancer	6.73e-07	1.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.69e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—hematologic cancer	6.66e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—hematologic cancer	6.64e-07	1.14e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—hematologic cancer	6.6e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—hematologic cancer	6.59e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—hematologic cancer	6.56e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—hematologic cancer	6.55e-07	1.13e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—hematologic cancer	6.54e-07	1.12e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—hematologic cancer	6.44e-07	1.11e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—hematologic cancer	6.4e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—hematologic cancer	6.39e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—hematologic cancer	6.37e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOR1—hematologic cancer	6.36e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—hematologic cancer	6.36e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3R1—hematologic cancer	6.35e-07	1.09e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	6.33e-07	1.09e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—hematologic cancer	6.26e-07	1.08e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—hematologic cancer	6.15e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—hematologic cancer	6.13e-07	1.06e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—hematologic cancer	6.1e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—hematologic cancer	6.06e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—hematologic cancer	5.92e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—hematologic cancer	5.87e-07	1.01e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—hematologic cancer	5.86e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—hematologic cancer	5.86e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—hematologic cancer	5.76e-07	9.91e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—hematologic cancer	5.74e-07	9.89e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—hematologic cancer	5.71e-07	9.83e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—hematologic cancer	5.7e-07	9.81e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—hematologic cancer	5.62e-07	9.67e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—hematologic cancer	5.57e-07	9.59e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOR1—hematologic cancer	5.57e-07	9.59e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—hematologic cancer	5.49e-07	9.45e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—hematologic cancer	5.47e-07	9.42e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—hematologic cancer	5.44e-07	9.36e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—hematologic cancer	5.34e-07	9.19e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—hematologic cancer	5.28e-07	9.08e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—hematologic cancer	5.26e-07	9.06e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—hematologic cancer	5.22e-07	8.98e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—hematologic cancer	5.18e-07	8.92e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—hematologic cancer	5.12e-07	8.8e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—hematologic cancer	5.07e-07	8.72e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—hematologic cancer	5.03e-07	8.66e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.95e-07	8.52e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—hematologic cancer	4.92e-07	8.47e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—hematologic cancer	4.85e-07	8.35e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—hematologic cancer	4.83e-07	8.31e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—hematologic cancer	4.72e-07	8.12e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—hematologic cancer	4.69e-07	8.08e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—hematologic cancer	4.51e-07	7.77e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—hematologic cancer	4.49e-07	7.72e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—hematologic cancer	4.44e-07	7.65e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CREBBP—hematologic cancer	4.38e-07	7.53e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—hematologic cancer	4.29e-07	7.39e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—hematologic cancer	4.23e-07	7.29e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—hematologic cancer	4.15e-07	7.14e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—hematologic cancer	4.14e-07	7.12e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—hematologic cancer	4.06e-07	6.99e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—hematologic cancer	3.96e-07	6.82e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3R1—hematologic cancer	3.92e-07	6.74e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	3.86e-07	6.64e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CREBBP—hematologic cancer	3.84e-07	6.6e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—hematologic cancer	3.69e-07	6.35e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.64e-07	6.26e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—hematologic cancer	3.62e-07	6.23e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—hematologic cancer	3.59e-07	6.18e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—hematologic cancer	3.57e-07	6.15e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.43e-07	5.91e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—hematologic cancer	3.32e-07	5.71e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.17e-07	5.45e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—hematologic cancer	3.15e-07	5.43e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—hematologic cancer	3.13e-07	5.38e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—hematologic cancer	2.98e-07	5.13e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—hematologic cancer	2.92e-07	5.02e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—hematologic cancer	2.74e-07	4.71e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—hematologic cancer	2.61e-07	4.5e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—hematologic cancer	2.21e-07	3.8e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.93e-07	3.33e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—hematologic cancer	1.8e-07	3.1e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—hematologic cancer	1.58e-07	2.72e-06	CbGpPWpGaD
